{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-021868","form_type":"8-K","ticker":"RLAY","cik":"0001812364","company_name":"Relay Therapeutics, Inc.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.260239+00:00","generated_at":"2026-06-22T09:45:28.681620+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Relay Therapeutics Q3 net loss $84.2M ($0.76/sh); RLY-4008 88% ORR in FGFR2-fusion CCA","bullets":["Net loss $84.2M vs $60.8M YoY; R&D expenses rose to $66.9M from $45.0M.","Cash and investments $1.1B as of Sep 30, 2022; sufficient to fund operations into 2025.","RLY-4008 interim data: 88% ORR at pivotal dose in FGFRi-naive FGFR2-fusion cholangiocarcinoma (n=17).","Raised $300M gross proceeds in follow-on public offering during Q3.","RLY-2608 (PI3Kα inhibitor) continues enrolling in single-agent and combination cohorts."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-021868","json":"https://secwatch.observer/filing/0000950170-22-021868.json","markdown":"https://secwatch.observer/filing/0000950170-22-021868.md","text":"https://secwatch.observer/filing/0000950170-22-021868.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1812364/000095017022021868/0000950170-22-021868-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1812364/000095017022021868/rlay-20221103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T09:45:28.681620+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d047b0c3a5a66ec8cd0104a43aeaa16647baa2b2","claim":"Relay Therapeutics, Inc. reported the quarter ended September 30, 2022 results: net income Net loss was $84.2 million for the third quarter of 2022, or a net loss per share of $0.76, EPS $0.76.","evidence_excerpt":"Relay Therapeutics, Inc. announced its financial results for the quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1812364/000095017022021868/0000950170-22-021868-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Net income","value":"Net loss was $84.2 million for the third quarter of 2022, or a net loss per share of $0.76"},{"label":"EPS","value":"$0.76"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}